It’s not all in the numbers

Journal of Nuclear Cardiology

Volumn 23, Issue 3, 2016, Pages 436-441

  Travin, Mark I ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMMONIA N 13; FLUORODEOXYGLUCOSE F 18; HUMAN SERUM ALBUMIN; NORADRENALIN; TECHNETIUM 99M; THALLIUM 201;

ADRENERGIC NERVE; BRUGADA SYNDROME; CARDIAC IMAGING; CARDIAC MUSCLE; CARDIOLOGY; CARDIOVASCULAR MORTALITY; DIAGNOSTIC ACCURACY; EDITORIAL; ELECTROCARDIOGRAPHY; GEOMETRY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HEART VENTRICLE WALL; HUMAN; ISCHEMIC CARDIOMYOPATHY; MYOCARDIAL PERFUSION IMAGING; NONISCHEMIC CARDIOMYOPATHY; NUCLEAR MEDICINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUDDEN CARDIAC DEATH;

EID: 84925422704     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-015-0105-8     Document Type: Editorial

References (73)

1. Zaret BL, Strauss HW, Hurley PJ, Natarajan TK, Pitt B. A noninvasive scintigraphic method for detecting regional ventricular dysfunction in man. N Engl J Med 1971;284:1165-70.
2. Parker JA, Secker-Walker R, Hill R, Siegel BA, Potchen EJ. A new technique for the calculation of left ventricular ejection fraction. J Nucl Med 1972;13:649-51.
3. Lebowitz E, Greene MW, Fairchild R, Bradley-Moore PR, Atkins HL, Ansari AN, et al. Thallium-201 for medical use I. J Nucl Med 1975;16:151-5.
4. Strauss HW, Harrison K, Langan JK, Lebowitz E, Pitt B. Thallium-201 for myocardial imaging. Relation of thallium-201 to regional myocardial perfusion. Circulation 1975;51:641-5.
5. Goris ML, Daspit SG, McLaughlin P, Kriss JP. Interpolative background subtraction. J Nucl Med 1976;17:7.
6. Ritchie JL, Zaret BL, Strauss HW, Pitt B, Berman DS, Schelbert HR, et al. Myocardial imaging with thallium-201: A multicenter study in patients with angina pectoris or acute myocardial infarction. Am J Cardiol 1978;42:345-50.
7. Berger BC, Watson DD, Taylor GJ, Craddock GB, Martin RP, Teates CD, et al. Quantitative thallium-201 exercise scintigraphy for detection of coronary artery disease. J Nucl Med 1981;22:585-93.
8. Watson DD, Campbell NP, Read EK, Gibson RS, Teates CD, Beller GA. Spatial and temporal quantitation of plane thallium myocardial images. J Nucl Med 1981;22:577-84.
9. Meade RC, Bameah VS, Horgan JD, Ruetz PP, Kronenwetter C, Yeh EL. Quantitative methods in the evaluation of thallium-201 myocardial perfusion images. J Nucl Med 1978;19:1175-8.
10. Vogel RA, Kirch DL, LeFree MT, Rainwater JO, Jensen DP, Steele PP. Thallium-201 myocardial perfusion scintigraphy: Results of standard and multi-pinhole tomographic techniques. Am J Cardiol 1979;43:787-93.
11. Burow RD, Pond M, Schafer W, Becker L. “Circumferential profiles:” A new method for computer analysis of thallium-201 myocardial perfusion images. J Nucl Med 1979;20:771-7.
12. Garcia E, Maddahi J, Berman D, Waxman A. Space/time quantitation of thallium-201 myocardial scintigraphy. J Nucl Med 1981;22:309-17.
13. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979;300:1350-8.
14. Garcia EV, Van Train K, Maddahi J, Prigent F, Friedman J, Areeda J, et al. Quantification of rotational thallium-201 myocardial tomography. J Nucl Med 1985;26:17-26.
15. DePasquale EE, Nody AC, DePuey EG, Garcia EV, Pilcher G, Bredlau C, et al. Quantitative rotational thallium-201 tomography for identifying and localizing coronary artery disease. Circulation 1988;77:316-27.
16. Garcia EV, Cooke CD, Van Train KF, Folks R, Peifer R, DePuey EG, et al. Technical aspects of myocardial SPECT imaging with technetium-99 m sestamibi. Am J Cardiol 1990;66:22E-31E.
17. Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Hsiao-Te S, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 1995;36:2138-47.
18. Germano G, Kavanagh PB, Waechter P, Areeda J, Van Kriekinge S, Sharir T, et al. A new algorithm for the quantitation of myocardial perfusion SPECT. I: Technical principles and reproducibility. J Nucl Med 2000;41:712-9.
19. Slomka PJ, Nishina H, Berman DS, Akincioglu C, Abidov A, Friedman JD, et al. Automated quantification of myocardial perfusion SPECT using simplified normal limits. J Nucl Cardiol 2005;12:66-77.
20. Slomka P, Xu Y, Berman D, Germano G. Quantitative analysis of perfusion studies: Strengths and pitfalls. J Nucl Cardiol 2012;19:338-46.
21. Xu Y, Hayes S, Ali I, Ruddy TD, Wells RG, Berman DS, et al. Automatic and visual reproducibility of perfusion and function measures for myocardial perfusion SPECT. J Nucl Cardiol 2010;17:1050-7.
22. Berman DS, Kang X, Gransar H, Gerlach J, Friedman J, Hayes S, et al. Quantitative assessment of myocardial perfusion abnormality on SPECT myocardial perfusion imaging is more reproducible than expert visual analysis. J Nucl Cardiol 2009;16:45-53.
23. Van Train KF, Areeda J, Garcia EV, Cooke CD, Maddahi J, Kiat H, et al. Quantitative same-day rest-stress technetium-99 m-sestamibi SPECT: Definition and validation of stress normal limits and criteria for abnormality. J Nucl Med 1993;34:1494-502.
24. Sharir T, Germano G, Waechter PB, Kavanagh PB, Areeda JS, Gerlach J, et al. A new algorithm for the quantitation of myocardial perfusion SPECT. II: Validation and diagnostic yield. J Nucl Med 2000;41:720-7.
25. Arsanjani R, Xu Y, Hayes SW, Fish M, Lemley M Jr, Gerlach J, et al. Comparison of fully automated computer analysis and visual scoring for detection of coronary artery disease from myocardial perfusion SPECT in a large population. J Nucl Med 2013;54:221-8.
26. Leslie WD, Tully SA, Yogendran MS, Ward LM, Nour KA, Metge CJ. Prognostic value of automated quantification of 99 mTc-sestamibi myocardial perfusion imaging. J Nucl Med 2005;46:204-11.
27. Xu Y, Nakazato R, Hayes S, Hachamovitch R, Cheng VY, Gransar H, et al. Prognostic value of automated vs visual analysis for adenosine stress myocardial perfusion SPECT in patients without prior coronary artery disease: A case-control study. J Nucl Cardiol 2011;18:1003-9.
28. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden. Results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283-91.
29. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). https://clinicaltrials.gov/ct2/show/NCT01471522. Accessed 2 Dec 2015.
30. 99mTc-sestamibi. Circulation 1994;89:2552-61.
31. Kitsiou AN, Srinivasan G, Quyyumi AA, Summers RM, Bacharach SL, Dilsizian V. Stress-induced reversible and mid-to-moderate irreversible thallium defects: Are they equally accurate for predicting recovery of regional left ventricular function after revascularization? Circulation 1998;98:501-8.
32. deKemp RA, Nahmias C. Automated determination of the left ventricular long axis in cardiac positron emission. Physiol Meas 1996;17:95-108.
33. deKemp R, Ruddy TD, Hewitt T, Dalipaj M, Beanlands R. Detection of serial changes in absolute myocardial perfusion with 82-Rb PET. J Nucl Med 2000;41:1426-35.
34. Laubenbacher C, Rothley J, Sitomer J, Beanlands R, Sawada S, Sutor R, et al. An automated analysis program for the evaluation of cardiac PET studies: Initial results in the detection and localization of coronary artery disease using nitrogen-13 ammonia. J Nucl Med 1993;34:968-78.
35. Beanlands RSB, Ruddy TD, deKemp RA, Iwanochko RM, Coates G, Freeman M, et al. Positron emission tomography and recovery following revascularization (PARR-1): The importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 2002;40:1735-43.
36. Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. PARR-2 Investigators. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: A randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007;50:2002-12.
37. D’Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation. J Am Coll Cardiol Imaging 2009;2:1060-8.
38. Travin MI. Cardiac autonomic imaging with SPECT tracers. J Nucl Cardiol 2013;20:128-43.
39. Thackeray JT, Bengel FM. Assessment of cardiac autonomic neuronal function using PET imaging. J Nucl Cardiol 2013;20:150-65.
40. Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981;22:129-32.
41. Schofer J, Spielmann R, Schuchert A, Weber K, Schlüter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: A noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252-8.
42. Merlet P, Valette H, Dubois-Randé J, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine in patients with heart failure. J Nucl Med 1992;33:471-7.
43. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: A systematic review. Eur Heart J 2008;29:1147-59.
44. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.
45. Minardo JD, Tuli MM, Mock BH, Weiner RE, Pride HP, Wellmann HN, et al. Scintigraphic and electrophysiologic evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 1988;78:1008-19.
46. Zipes DP. Influence of myocardial ischemia and infarction on autonomic innervation of heart. Circulation 1991;84:1709-14.
47. Gerson MC, Abdallah M, Muth JN, Costea AI. Will imaging assist in the selection of patients with heart failure for an ICD? J Am Coll Cardiol Imaging 2010;3:101-10.
48. 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis. Eur Heart J Cardiovasc Imaging 2014;15:996-1003.
49. Stanton MS, Tuli MM, Radtke NL, Heger JJ, Miles WM, Mock BH, et al. Regional sympathetic denervation after MI in humans detected noninvasively using I-123-MIBG. J Am Coll Cardiol 1989;14:1519-26.
50. McGhie AI, Corbett JR, Akers MS, Kulkarni P, Sills MN, Kremers M, et al. Regional cardiac adrenergic function using I-123 MIBG SPECT imaging after acute myocardial infarction. Am J Cardiol 1991;67:236-42.
51. Simões MV, Barthel P, Matsunari I, Nekolla SG, Schömig A, Schwaiger M, et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J 2004;25:551-7.
52. Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 MIBG imaging and heart rate variability analysis to predict the needs for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121-31.
53. 123I-mIBG Scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: A prospective multicenter pilot study. Circ Cardiovasc Imaging 2008;1:131-40.
54. Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, et al. Cardiac sympathetic denervation assessed with 123-Iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;55:2769-77.
55. Marshall A, Cheetham A, George RS, Mason M, Kelion AD. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts ventricular arrhythmia in heart failure patients receiving an implantable cardioverter-defibrillator for primary prevention. Heart 2012;98:1359-65.
56. Wichter T, Matheja P, Eckardt L, Kies P, Schäfers K, Schulze-Bahr E, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 2002;105:702-6.
57. Paul M, Wichter T, Kies P, Gerss J, Wollmann C, Rahbar K, et al. Cardiac sympathetic dysfunction in genotyped patients with arrhythmogenic right ventricular cardiomyopathy and risk of recurrent ventricular tachyarrhythmias. J Nucl Med 2011;52:1559-65.
58. Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldwa S, Mashtare TL, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 2014;63:141-9.
59. Clements I, Garcia E, Chen J, Folks R, Butler J, Jacobson A. Quantitative iodine 123 meta-iodobenzylguanidine (MIBG) SPECT imaging in heart failure with left ventricular systolic dysfunction: Development and validation of automated procedures in conjunction with technetium-99m tetrofosmin myocardial perfusion SPECT. J Nucl Cardiol 2015. doi:10.1007/s12350-015-0097-4.
60. Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: Design of two prospective multicenter international trials. J Nucl Cardiol 2009;16:113-21.
61. Chen J, Garcia EV, Galt JR, Folks RD, Carrió I. Improved quantification in I-123 cardiac SPECT imaging with deconvolution of septal penetration. Nucl Med Commun 2006;27:551-8.
62. Garcia EV, Faber TL, Cooke CD, Folks RD, Chen J, Santana C. The increasing role of quantification in clinical nuclear cardiology: The Emory approach. J Nucl Cardiol 2007;14:420-32.
63. Rischpler C, Nekolla S, Schwaiger M. PET and SPECT in heart failure. Curr Cardiol Rep 2013;15:337. doi:10.1007/s11886-012-0337-z.
64. Wu YW, Yen RF, Chieng PU, Huang PJ. Tl-201 myocardial SPECT in differentiation of ischemic from nonischemic dilated cardiomyopathy in patients with left ventricular dysfunction. J Nucl Cardiol 2003;10:369-74.
65. Yao S, Qureshi E, Nichols K, Diamond GA, DePuey EG. Prospective validation of a quantitative method for differentiating ischemic versus nonischemic cardiomyopathy by technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. Clin Cardiol 2004;27:615-20.
66. 123I-mIBG and 99mTc-tetrofosmin SPECT for prediction of arrhythmic risk in ischemic heart failure patients. J Nucl Med 2014;55:182.
67. Gimelli A, Liga R, Giorgetti A, Genovesi D, Marzullo P. Assessment of myocardial adrenergic innervation with a solid-state dedicated cardiac cadmium-zinc-telluride camera: First clinical experience. Eur Heart J CV Imaging 2014;15:575-85.
68. Hachamovitch R, Berman DS. The use of nuclear cardiology in clinical decision making. Semin Nucl Med 2005;35:62-72.
69. Chirumamilla A, Travin MI. Cardiac applications of 123I-mIBG imaging. Semin Nucl Med 2011;41:374-87.
70. 99mTc-tetrofosmin SPECT for the prediction of arrhythmic events in ischemic heart failure patients. J Nucl Cardiol 2014;21:799.
71. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004;95:754-63.
72. Luisi AJ Jr, Suzuki G, Dekemp R, Haka MS, Toorongian SA, Canty JM Jr, et al. Regional 11C-Hydroxyephedrine retention in hibernating myocardium: Chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med 2005;46:1368-74.
73. Zhou Y, Zhou W, Folks RD, Manatunga DN, Jacobson AF, Bax JJ, et al. I-123 mIBG and Tc-99m myocardial SPECT imaging to predict inducibility of ventricular arrhythmia on electrophysiology testing: A retrospective analysis. J Nucl Cardiol 2014;21:913-20.